FDA extends premarket approval (PMA) review programme:
This article was originally published in Clinica
Executive Summary
The FDA's Center for Devices & Radiological Health has extended its successful pilot programme for the "real-time" review of PMA supplements to all divisions and branches. Companies can qualify for the programme if they meet criteria specified for their product area.